

The role of inflammatory factors in the pathogenesis of osteoporosis

Published: 11-08-2006

Last updated: 14-05-2024

Answering the following research questions: 1. Have circulating inflammatory factors a central role in the pathogenesis of regional and general osteoporosis in different inflammatory diseases? 2. Which inflammatory factors have a key role in this...

Ethical review	Approved WMO
Status	Pending
Health condition type	Autoimmune disorders
Study type	Observational non invasive

Summary

ID

NL-OMON29779

Source

ToetsingOnline

Brief title

Inflammatory factors & Osteoporosis

Condition

- Autoimmune disorders
- Bone disorders (excl congenital and fractures)

Synonym

osteoporosis ; weakening bone disorder

Research involving

Human

Sponsors and support

Primary sponsor: Vrije Universiteit Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: inflammatory factors, osteoporosis

Outcome measures

Primary outcome

Proliferation and differentiation parameters

Secondary outcome

not applicable

Study description

Background summary

In patients with rheumatoid arthritis bone loss in specific joints is caused by the inflammation of these joints. However, at the long term also general osteoporosis occurs. In patients with fractures a similar phenomenon has been observed. And a third group of patients in which relatively often general osteoporosis is found, are patients with Crohn's disease.

A resemblance between these patientgroups is the presence of inflammatory factors, both locally and systemic. Possibly inflammatory factors are involved in the pathogenesis of osteoporosis.

Study objective

Answering the following research questions:

1. Have circulating inflammatory factors a central role in the pathogenesis of regional and general osteoporosis in different inflammatory diseases?
2. Which inflammatory factors have a key role in this process?
3. Is it possible to inhibit or prevent the pathogenesis of osteoporosis by inhibiting specific inflammatory factors, like TNFa which is inhibited by infliximab?

Study design

Observational

Study burden and risks

not applicable

Contacts

Public

Vrije Universiteit Medisch Centrum

De Boelelaan 1117
1081 HV Amsterdam
Nederland

Scientific

Vrije Universiteit Medisch Centrum

De Boelelaan 1117
1081 HV Amsterdam
Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Healthy persons undergoing a bone transplantation from the pelvis for jaw surgery purposes

Exclusion criteria

Unhealthy persons

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-05-2006

Enrollment: 30

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL12145.029.06